

Supporting Information

for

Highly efficient organocatalysts for the asymmetric aldol reaction

C. G. Jacoby, Pedro H. V. Vontobel, M. F. Bach and P. H. Schneider*

Instituto de Química, Universidade Federal do Rio Grande do Sul (UFRGS), PO Box 15003, 91501-970 Porto Alegre-RS, Brazil.
paulos@iq.ufrgs.br

Experimental Section

General Information

The NMR spectra were recorded on 400 MHz spectrometer Varian Inova 400 e Bruker Avance 400. Chemical shifts (δ) are expressed in ppm downfield from TMS as internal standard in spectra made in CDCl₃. Coupling constants are reported in Hz. All enantiomeric excesses were obtained from HPLC using chiral stationary phase in a Shimadzu LC-20AT chromatograph. Optical rotations were obtained in a Jasco P-2000 polarimeter. Melting points were obtained in a Buchi Melting Point M-560 equipment. Infrared spectra were obtained in a Shimadzu IR Prestige-21 spectrometer. HRMS spectra were obtained in a Micromass Q-ToF micro mass spectrometer. All the column chromatography separations were done by using silica gel 230-400 Mesh. Solvents were purified by usual methods.¹ Other reagents were obtained from commercial source and used without further purification.

General procedure for the synthesis of phenacyl esters 3a-e

The amino acid (5 mmol) was added to a solution of triethylamine (0.8 mL, 5 mmol) in ethyl acetate (30 mL) at room temperature. Then the corresponding 2-bromoacetophenone (5 mmol) was introduced and the reaction mixture was stirred for 24 h. The reaction was treated with aqueous NaHCO₃ 5% solution (30 mL) and the aqueous phase was extracted with ethyl acetate (3 x 20 mL). The organic extracts were

combined, washed with water (3 x 20 mL), dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The residue was used without further purification.

3-(*tert*-butyl) 4-(2-oxo-2-phenylethyl) (*R*)-thiazolidine-3,4-dicarboxylate (3a)

The product was obtained as a white solid. Yield: 90 %. Mp 88-92 °C. $[\alpha]_D^{20} = -59$ (c 0.4, CH₂Cl₂). IR (KBr): 3392, 3007, 2981, 2936, 2890, 1760, 1706, 1388, 1367, 1174, 1137. ¹H NMR (400 MHz, CDCl₃, conformer mixture) δ: 7.90 (d, *J* = 7.6 Hz, 2H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.49 (t, *J* = 7.4 Hz, 2H), [5.58 (d, *J* = 16.3 Hz), 5.47 (d, *J* = 16.4 Hz), 5.36 (d, *J* = 16.1 Hz) and 5.26 (d, *J* = 16.4 Hz), 2H], [5.05-4.93 (m) and 4.92-4.78 (m), 1H], 4.66 (d, *J* = 8.5 Hz, 1H), 4.57-4.45 (m, 1H), 3.55-3.35 (m, 2H), 1.48 (s, 9H). ¹³C NMR (100 MHz, CDCl₃, conformer mixture) δ: 191.6, 191.2, 170.3, 170.2, 153.3, 153.1, 134.0, 133.9, 128.9, 127.7, 81.3, 66.5, 61.3, 49.1, 48.5, 34.7, 33.5, 28.3, 28.2.

3-(*tert*-butyl) 4-(2-(4-methoxyphenyl)-2-oxoethyl) (*R*)-thiazolidine-3,4-dicarboxylate (3b)

The product was obtained as a brown oil. Yield: 79 %. $[\alpha]_D^{20} = -16$ (c 0.5, CH₂Cl₂). IR (film): 3009, 2972, 2935, 2841, 1758, 1704, 1690, 1601, 1385, 1370, 1241, 1169. ¹H NMR (400 MHz, CDCl₃, conformer mixture) δ: 7.87 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), [5.53 (d, *J* = 16.2 Hz), 5.42 (d, *J* = 16.0 Hz), 5.30 (d, *J* = 15.9 Hz) and 5.21 (d, *J* = 16.6 Hz), 2H], [5.03-4.94 (m) and 4.89-4.80 (m), 1H], 4.65 (d, *J* = 8.7 Hz, 1H), 4.56-4.46 (m, 1H), 3.87 (s, 3H), 3.56-3.36 (m, 2H), 1.54-1.37 (m, 9H). ¹³C NMR (100 MHz, CDCl₃, conformer mixture) δ: 190.0, 189.6, 170.4, 170.3, 164.1, 163.4, 153.3, 153.1, 131.1, 130.0, 126.9, 114.1, 113.8, 81.3, 66.4, 66.2, 61.3, 55.5, 49.1, 48.6, 34.8, 34.4, 28.3, 28.2.

4-(2-(4-bromophenyl)-2-oxoethyl) 3-(*tert*-butyl) (*R*)-thiazolidine-3,4-dicarboxylate (3c)

The product was obtained as a yellow oil. Yield: 90 %. $[\alpha]_D^{20} = -24$ (c 0.6, CH₂Cl₂). IR (film): 3382, 3087, 2975, 2936, 2882, 1755, 1706, 1679, 1587, 1168, 1071. ¹H NMR (400 MHz, CDCl₃, conformer mixture) δ: 7.69 (d, *J* = 8.4 Hz, 2H), 7.57 (d, *J* = 8.3 Hz, 2H), [5.45 (d, *J* = 16.3 Hz), 5.35 (d, *J* = 16.2 Hz), 5.24 (d, *J* = 16.3 Hz) and 5.15 (d, *J* = 16.4 Hz), 2H], [4.92 (dd, *J* = 6.0; 3.9 Hz) and 4.84-4.74 (m), 1H], 4.58 (d, *J* = 8.7 Hz, 1H), 4.44 (d, *J* = 9.0 Hz, 1H), 3.45-3.28 (m, 2H), 1.48-1.32 (m, 9H). ¹³C NMR (100

MHz, CDCl₃, conformer mixture) δ : 190.8, 190.4, 170.3, 170.1, 153.3, 153.1, 132.6, 132.3, 131.8, 131.6, 129.2, 81.4, 66.3, 61.3, 49.1, 48.5, 34.7, 33.5, 28.3, 28.2.

3-(*tert*-butyl) 4-(2-(4-nitrophenyl)-2-oxoethyl) (*R*)-thiazolidine-3,4-dicarboxylate (3d)

The product was obtained as a yellow wax. Yield: 96 %. $[\alpha]_D^{20} = -46$ (*c* 0.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, conformer mixture) δ : 8.36 (d, *J* = 8.6 Hz, 2H), 8.08 (d, *J* = 8.6 Hz, 2H), [5.57 (d, *J* = 16.4 Hz), 5.48 (d, *J* = 16.5 Hz), 5.38 (d, *J* = 16.4 Hz) and 5.28 (d, *J* = 16.7 Hz), 2H], [5.04-4.96 (m) and 4.93-4.83 (m), 1H], 4.74-4.57 (m, 1H), 4.51 (dd, *J* = 15.1; 8.9 Hz, 1H), 3.50-3.39 (m, 2H), 1.47 (s, 9H). ¹³C NMR (100 MHz, CDCl₃, conformer mixture) δ : 190.6, 190.2, 170.2, 170.1, 153.2, 153.0, 150.7, 138.8, 131.0, 129.0, 124.1, 123.5, 81.4, 66.6, 66.5, 61.3, 49.0, 48.5, 34.6, 33.4, 28.2.

1-(*tert*-butyl) 2-(2-oxo-2-phenylethyl) (*S*)-pyrrolidine-1,2-dicarboxylate (3e)

The product was obtained as a white solid. Yield: 85 %. Mp 78-81 °C. $[\alpha]_D^{20} = -54$ (*c* 1, CH₂Cl₂) [lit.² Mp 80-83 °C, $[\alpha]_D^{20} = -67.8$ (*c* 1, DMF)]. IR (KBr): 3394, 3025, 2976, 2936, 2893, 1758, 1707, 1597, 1450, 1398, 1370, 1171, 1119. ¹H NMR (400 MHz, CDCl₃, conformer mixture) δ : 7.93-7.87 (m, 2H), 7.65-7.57 (m, 1H), 7.46-7.54 (m, 2H), [5.57 (d, *J* = 16.4 Hz), 5.42 (d, *J* = 16.3 Hz), 5.34 (d, *J* = 16.3 Hz) and 5.22 (d, *J* = 16.4 Hz), 2H], 4.49 (dd, *J* = 8.5; 3.7 Hz) and 4.48-4.36 (m), 1H], 3.64-3.51 (m, 1H), 3.51-3.35 (m, 1H), 2.40-2.22 (m, 2H), 2.15-1.98 (m, 1H), 1.98-1.77 (m, 1H), 1.60-1.38 (m, 9H). ¹³C NMR (100 MHz, CDCl₃, conformer mixture) δ : 192.2, 191.8, 172.6, 172.5, 154.5, 153.9, 134.2, 134.1, 134.0, 133.9, 128.9, 128.8, 127.7, 80.0, 79.9, 66.1, 65.9, 59.0, 58.7, 46.7, 46.4, 31.0, 30.1, 28.5, 28.4, 24.3, 23.6.

General procedure for the synthesis of compounds 5a-e

Ammonium acetate (1.54 g, 20 mmol) was added to a solution of the corresponding phenacyl ester (2 mmol) in toluene (20 mL). The mixture was refluxed with a Dean-Stark trap for 19 h. Then the reaction was cooled to room temperature and poured into water (20 mL). The organic layer was washed with saturated aqueous NaHCO₃ solution (20 mL) and water (20 mL), dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (2 mL) and a solution of

TFA (4 mL) in ethyl acetate (4 mL) was added. The mixture was stirred at room temperature and the reaction was monitored by TLC. After 1-2 h, the mixture was neutralized with K_2CO_3 and the aqueous layer was extracted with ethyl acetate (3 x 5 mL). The organic extracts were combined, washed with water, dried over Na_2SO_4 , filtrated and concentrated under reduced pressure. The product was purified with flash column chromatography on silica gel using ethyl acetate.

(R)-4-(5-phenyl-1H-imidazol-2-yl)thiazolidine (5a)

The product was obtained as a yellow solid. Yield: 91 %. Mp 178-182 °C. $[\alpha]_D^{20} = -19$ (c 0.3, CH_2Cl_2). IR (KBr): 3042, 2979, 2945, 1684, 1441, 1208, 1140. 1H NMR (400 MHz, $DMSO-d_6$) δ : 12.3 (bs, 1H), 7.74 (d, $J = 7.2$ Hz, 2H), 7.48 (s, 1H), 7.33 (t, $J = 7.7$ Hz, 2H), 7.17 (t, $J = 7.4$ Hz, 1H), 4.40 (t, $J = 6.4$ Hz, 1H), 4.17 (s, 2H), 3.23 (dd, $J = 9.8$; 6.4 Hz, 1H), 3.16 (dd, $J = 9.8$; 6.4 Hz, 1H). ^{13}C NMR (100 MHz, $DMSO-d_6$) δ : 147.1, 133.9, 128.5, 126.0, 124.2, 113.9, 61.9, 53.9, 37.4. HRMS calculated for $[C_{12}H_{13}N_3S+H]^+$: 232.0909, obtained: 232.0986.

(R)-4-(5-(4-methoxyphenyl)-1H-imidazol-2-yl)thiazolidine (5b)

The product was obtained as a brown solid. Yield: 83 %. Mp 166-169 °C. $[\alpha]_D^{20} = -50$ (c 0.3, CH_2Cl_2). IR (KBr): 3055, 2946, 2887, 1687, 1208, 1141. 1H NMR (400 MHz, $CDCl_3$) δ : 7.65-7.40 (m, 2H), 7.08 (s, 1H), 6.93-6.65 (m, 2H), 4.32-4.05 (m, 1H), 3.90-3.55 (m, 5H), 3.50-2.95 (m, 2H). ^{13}C NMR (100 MHz, $DMSO-d_6$) δ : 157.9, 130.2, 126.6, 125.6, 114.2, 114.0, 55.2, 55.0. HRMS calculated for $[C_{13}H_{15}N_3OS+H]^+$: 262.1014, obtained: 262.1082.

(R)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)thiazolidine (5c)

The product was obtained as a yellow solid. Yield: 93 %. Mp 174-178 °C. $[\alpha]_D^{20} = -34$ (c 0.3, CH_2Cl_2). IR (film): 3261, 3035, 2981, 2943, 2893, 1687, 1476, 1435, 1208, 1140. 1H NMR (400 MHz, $CDCl_3$) δ : 7.54 (d, $J = 8.6$ Hz, 2H), 7.42 (d, $J = 8.6$ Hz, 2H), 7.18 (s, 1H), 4.45 (t, $J = 6.8$ Hz, 1H), 4.20 (s, 2H), 3.33 (dd, $J = 10.3$; 6.8 Hz, 1H), 3.28 (dd, $J = 10.3$; 6.8 Hz, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ : 148.7, 147.4, 132.0, 131.8, 126.4, 120.9, 114.6, 61.4, 50.7, 37.4. HRMS calculated for $[C_{12}H_{12}BrN_3S+H]^+$: 310.0013, obtained: 309.9938.

(R)-4-(5-(4-nitrophenyl)-1H-imidazol-2-yl)thiazolidine (5d)

The product was obtained as a yellow solid. Yield: 95 %. Mp 185-190 °C. $[\alpha]_D^{20} = -23$ (c 0.2, CH₂Cl₂). IR (KBr): 3265, 3021, 2981, 2946, 2885, 1588, 1506, 1333, 1146, 1111. ¹H NMR (400 MHz, CDCl₃) δ: 8.18 (d, *J* = 8.9 Hz, 2H), 7.89 (d, *J* = 8.9 Hz, 2H), 7.50 (s, 1H), 4.99-4.92 (m, 1H), 4.34-4.30 (m, 2H), 3.64 (dd, *J* = 11.2; 8.4 Hz, 1H), 3.47 (dd, *J* = 11.1; 6.3 Hz, 1H). ¹³C NMR (100 MHz, DMSO-d₆) δ: 148.5, 145.1, 141.6, 137.8, 124.6, 124.1, 116.8, 61.8, 53.9, 37.2. HRMS calculated for [C₁₂H₁₂N₄O₂S+H]⁺: 277.0759, obtained: 277.0804.

(S)-5-phenyl-2-(pyrrolidin-2-yl)-1H-imidazole (5e)

The product was obtained as a brown oil. Yield: 81 %. $[\alpha]_D^{20} = -38$ (c 0.2, CH₂Cl₂). IR (film): 3036, 2948, 2913, 1655, 1450, 1402, 1290, 1186. ¹H NMR (400 MHz, CDCl₃) δ: 7.85 (s, 1H), 7.70 (d, *J* = 7.6 Hz, 2H), 7.39 (t, *J* = 7.4 Hz, 2H), 7.30 (t, *J* = 7.6 Hz, 1H), 4.54 (t, *J* = 6.7 Hz, 1H), 3.29-3.19 (m, 1H), 3.17-3.07 (m, 1H), 2.35-2.19 (m, 1H), 2.18-2.07 (m, 1H), 2.03-1.86 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ: 140.6, 133.9, 130.9, 128.8, 128.2, 125.6, 55.2, 46.3, 30.9, 25.2. HRMS calculated for [C₁₃H₁₅N₃+2H]⁺: 215.1422, obtained: 215.1365.

General procedure for organocatalytic asymmetric direct aldol reaction

A solution of organocatalyst **5d** (0.014 g, 0.05 mmol), benzoic acid (0.006 g, 0.05 mmol) and the corresponding ketone (5 mmol) was stirred at room temperature for 0.5 h. Then the system was cooled to 0 °C, the aldehyde (0.5 mmol) was added and the reaction mixture was stirred for 120 h. The solution was returned to room temperature, treated with saturated aqueous NH₄Cl solution (1 mL) and extracted with dichloromethane (3 x 2 mL). The organic extracts were combined, dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The product was purified with flash column chromatography on silica gel using ethyl acetate and hexane (20:80).

(S)-2-((R)-hydroxy(phenyl)methyl)cyclohexan-1-one (8a)

The product was obtained in 81 % yield with >99 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel OD-H, hexane/2-propanol 90:10, 221 nm, flow rate 0.5 mL/min: $t_{R(\text{maj})} = 17.9$ min (*S,R*); $t_{R(\text{min})} = 26.7$ min (*R,S*). $[\alpha]_D^{25} = +18$ (*c* 1, CHCl₃) [lit.³ $[\alpha]_D^{25} = +19$ (*c* 1, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 7.37-7.23 (m, 5H), 4.79 (d, *J* = 8.8 Hz, 1H), 3.99 (bs, 1H), 2.63 (ddd, *J* = 12.8; 8.8; 5.5 Hz, 1H), 2.48 (ddd, *J* = 13.7, 4.5, 3.0 Hz, 1H), 2.42-2.30 (m, 1H), 2.08 (dtt, *J* = 11.8; 5.7; 3.1 Hz, 1H), 1.83-1.74 (m, 1H), 1.73-1.60 (m, 1H), 1.62-1.46 (m, 2H), 1.36-1.22 (m, 1H).

(S)-2-((R)-hydroxy(p-tolyl)methyl)cyclohexan-1-one (8b)

The product was obtained in 42 % yield with >99 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 90:10, 220 nm, flow rate 0.5 mL/min: $t_{R(\text{maj})} = 23.1$ min (*S,R*). $[\alpha]_D^{25} = +17$ (*c* 0.2, CHCl₃) [lit.⁴ $[\alpha]_D^{24} = +12.9$ (*c* 0.17, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 7.15-6.90 (m, 4H), 4.68 (d, *J* = 8.7 Hz, 1H), 4.13 (bs, 1H), 2.58-1.85 (m, 4H), 1.73-1.35 (m, 5H).

(S)-2-((R)-(4-bromophenyl)(hydroxy)methyl)cyclohexan-1-one (8c)

The product was obtained in 99 % yield with 98 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 90:10, 220 nm, flow rate 1.0 mL/min: $t_{R(\text{maj})} = 13.8$ min (*S,R*); $t_{R(\text{min})} = 11.7$ min (*R,S*). $[\alpha]_D^{25} = +24$ (*c* 1, CHCl₃) [lit.⁴ $[\alpha]_D^{24} = +22.6$ (*c* 0.7, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 7.45 (d, *J* = 8.1 Hz, 2H), 7.18 (d, *J* = 8.1 Hz, 2H), 4.74 (d, *J* = 8.5 Hz, 1H), 2.65-2.15 (m, 3H), 2.13-1.90 (m, 1H), 1.83-1.35 (m, 4H), 1.32-1.10 (m, 1H).

4-((R)-hydroxy((S)-2-oxocyclohexyl)methyl)benzotrile (8d)

The product was obtained in 92 % yield with 99 % *ee* and 8:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 80:20, 220 nm, flow rate 0.5 mL/min: $t_{R(\text{maj})} = 24.2$ min (*R,S*); $t_{R(\text{min})} = 30.0$ min (*R,S*). ¹H NMR (400 MHz, CDCl₃) δ : 7.68-7.60 (m, 2H), 7.48-7.40 (m, 2H), 4.85 (d, *J* = 8.4 Hz, 1H), 4.08 (bs, 1H), 2.58 (dddd, *J* = 13.0, 8.4, 5.5, 1.2 Hz, 1H), 2.53-2.44 (m, 1H), 2.36 (td, *J* = 13.6, 6.1, 1.2 Hz, 1H), 2.17-2.06 (m, 1H), 1.87-1.78 (m, 1H), 1.75-1.52 (m, 3H), 1.40-1.32 (m, 1H).

(S)-2-((R)-hydroxy(4-nitrophenyl)methyl)cyclohexan-1-one (8e)

The product was obtained in 98 % yield with >99 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 90:10, 254 nm, flow rate 1.0 mL/min: $t_{R(\text{maj})} = 29.1$ min (*S,R*); $t_{R(\text{min})} = 21.8$ min (*R,S*). $[\alpha]_D^{25} = +10$ (*c* 1, CHCl₃) [lit.⁴ $[\alpha]_D^{25} = +12.8$ (*c* 1.85, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 8.21 (d, *J* = 8.3 Hz, 2H), 7.51 (d, *J* = 8.3 Hz, 2H), 4.90 (d, *J* = 8.3 Hz, 1H), 3.13 (bs, 1H), 2.65-2.25 (m, 3H), 2.18-2.03 (m, 1H), 1.90-1.45 (m, 5H).

(S)-2-((R)-hydroxy(3-nitrophenyl)methyl)cyclohexan-1-one (8f)

The product was obtained in 93 % yield with >99 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 95:05, 254 nm, flow rate 0.8 mL/min: $t_{R(\text{maj})} = 34.2$ min (*S,R*); $t_{R(\text{min})} = 45.2$ min (*R,S*). $[\alpha]_D^{25} = +26$ (*c* 1, CHCl₃) [lit.⁴ $[\alpha]_D^{25} = +32.5$ (*c* 1.35, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 8.17 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 1H), 7.64 (d, *J* = 7.1 Hz, 1H), 7.52-7.34 (m, 1H), 4.88 (d, *J* = 8.4 Hz, 1H), 4.45 (bs, 1H), 2.69-2.19 (m, 3H), 2.15-1.90 (m, 1H), 1.89-1.38 (m, 5H).

(S)-2-((R)-hydroxy(2-nitrophenyl)methyl)cyclohexan-1-one (8g)

The product was obtained in 99 % yield with 99 % *ee* and >19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 90:10, 254 nm, flow rate 1.0 mL/min: $t_{R(\text{maj})} = 16.5$ min (*S,R*); $t_{R(\text{min})} = 18.0$ min (*R,S*). $[\alpha]_D^{25} = +15$ (*c* 1, CHCl₃) [lit.⁴ $[\alpha]_D^{24} = +19.8$ (*c* 1.6, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 7.78 (d, *J* = 8.1 Hz, 1H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 7.7 Hz, 1H), 5.38 (d, *J* = 7.0 Hz, 1H), 2.69 (dt, *J* = 12.7; 6.4 Hz, 1H), 2.46-2.34 (m, 1H), 2.27 (td, *J* = 13.2; 6.1 Hz, 1H), 2.08-1.98 (m, 1H), 1.83-1.74 (m, 1H), 1.74-1.46 (m, 4H).

(S)-2-((R)-hydroxy(4-nitrophenyl)methyl)cyclopentan-1-one (8h)

The product was obtained in 81 % yield with 98 % *ee* and 3:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 90:10, 280 nm, flow rate 0.5 mL/min: $t_{R(\text{maj})} = 55.5$ min (*S,R*), $t_{R(\text{min})} = 52.5$ min (*R,S*). $[\alpha]_D^{25} = -25$ (*c* 0.5, CHCl₃) [lit.⁴ $[\alpha]_D^{25} = -30.6$ (*c* 0.56, CHCl₃)]. ¹H NMR (400 MHz, CDCl₃) δ : 8.22 (d,

$J = 8.8$ Hz, 2H), 7.54 (d, $J = 8.6$ Hz, 2H), 4.85 (d, $J = 9.8$ Hz, 1H), 2.55-2.25 (m, 2H), 2.23-1.90 (m, 3H), 1.85-1.65 (m, 2H).

(S)-2-((R)-hydroxy(2-nitrophenyl)methyl)cyclopentan-1-one (8i)

The product was obtained in 99 % yield with 99 % *ee* and 3:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel OD-H, hexane/2-propanol 95:5, 254 nm, flow rate 1.0 mL/min: $t_{R(\text{maj})} = 24.2$ min (*S,R*), $t_{R(\text{min})} = 26.3$ min (*R,S*). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 8.13-7.85 (m, 1H), 7.81 (td, $J = 8.1$; 1.3 Hz, 1H), 7.69-7.62 (m, 1H), 7.47-7.40 (m, 1H), 5.44 (d, $J = 8.5$ Hz, 1H), 4.49 (bs, 1H), 2.58-2.48 (m, 1H), 2.47-2.38 (m, 1H), 2.37-2.24 (m, 1H), 2.08-1.97 (m, 1H), 1.83-1.67 (m, 3H).

(S)-2-((R)-(4-bromophenyl)(hydroxy)methyl)cyclopentan-1-one (8j)

The product was obtained in 99 % yield with >99 % *ee* and 5:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AD-H, hexane/2-propanol 95:5, 220 nm, flow rate 1.0 mL/min: $t_{R(\text{maj})} = 22.3$ min (*S,R*). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 7.48-7.42 (m, 2H), 7.23-7.16 (m, 2H), 4.67 (d, $J = 9.1$ Hz, 1H), 2.47-2.29 (m, 2H), 2.18-2.12 (m, 1H), 2.00-1.90 (m, 2H), 1.80-1.62 (m, 2H).

Procedure for organocatalytic asymmetric Michael reaction

A solution of organocatalyst **5d** (0.014 g, 0.05 mmol), benzoic acid (0.006 g, 0.05 mmol) and the cyclohexanone (0.52 mL, 5 mmol) was stirred at room temperature for 0.5 h. β -nitrostyrene (0.075 g, 0.5 mmol) was then added and the reaction mixture was stirred for 72 h. The solution was treated with saturated aqueous NH_4Cl solution (1 mL) and extracted with dichloromethane (3 x 5 mL). The organic extracts were combined, dried over Na_2SO_4 , filtrated and concentrated under reduced pressure. The product was purified with flash column chromatography on silica gel using ethyl acetate and hexane (20:80).

(R)-2-((S)-2-nitro-1-phenylethyl)cyclohexan-1-one (10)

The product was obtained in 35% yield with >99 % *ee* and 19:1 *dr*. The enantiomeric excess was determined by HPLC on Chiralcel AS-H, hexane/2-propanol 75:25, 254 nm, flow rate 1.0 mL/min: $t_{R(\text{min})} = 8.23$ min (*R,S*). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 7.53-7.23

(m, 3H), 7.19-7.06 (m, 2H), 4.95 (dd, $J = 11.2$ Hz; 4.5 Hz, 1H), 4.56 (dd, 2H), 3.68 (dt, $J = 4.5$ Hz; 9.9 Hz, 1H), 2.67 (ddd, $J = 12.0$ Hz; 8.6 Hz, 8.0 Hz; 2H), 2.45-2.20 (m, 2H), 1.78-1.41 (m, 4H), 1.20-1.05 (m, 1H).

References

1. Purification of Laboratory Chemicals; D. D. Perrin and W. L. Armarego, Eds., 4a ed.; Pergamon: New York, 1997.
2. S. Kokinaki, L. Leondiadis and F. Nikolas, *Org. Lett.* 2005, **7**, 1723.
3. M. R. Vishnumaya and V. K. Singh, *J. Org. Chem.* 2009, **74**, 4289.
4. Y. Wu, Y. Zhang, M. Yu, G. Zhao and S. Wang, *Org. Lett.* 2006, **8**, 4417.

NMR spectra of catalysts and synthetic intermediates




Figure S1. ¹H NMR (400 MHz, CDCl₃) spectrum of **3a**.




Figure S2. ¹³C NMR (100 MHz, CDCl₃) spectrum of **3a**.




Figure S3. ¹H NMR (400 MHz, CDCl₃) spectrum of **3b**.




Figure S4. ¹³C NMR (100 MHz, CDCl₃) spectrum of **3b**.




Figure S5. ^1H NMR (400 MHz, CDCl_3) spectrum of **3c**.




Figure S6. ^{13}C NMR (100 MHz, CDCl_3) spectrum of **3c**.




Figure S7. ^1H NMR (400 MHz, CDCl_3) spectrum of **3d**.




Figure S8. ^{13}C NMR (100 MHz, CDCl_3) spectrum of **3d**.




Figure S9. ^1H NMR (400 MHz, CDCl_3) spectrum of compound **5e** precursor.




Figure S10. ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **5e** precursor.




Figure S11. ^1H NMR (400 MHz, DMSO-d_6) spectrum of **5a**.




Figure S12. ^1H - ^1H COSY (400 MHz, DMSO-d_6) spectrum of **5a**.




Figure S13. ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of **5a**.




Figure S14. ^1H - ^{13}C HSQC (400 MHz, DMSO-d_6) spectrum of **5a**.




Figure S15. ^1H - ^{13}C HMBC (400 MHz, DMSO-d_6) spectrum of **5a**.




Figure S16. ^1H NMR (400 MHz, $\text{CDCl}_3/\text{DMSO-d}_6$) spectrum of **5b**.




Figure S17. ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of **5b**.




Figure S18. ¹H NMR (400 MHz, CDCl₃) spectrum of **5c**.




Figure S19. ¹³C NMR (100 MHz, CDCl₃) spectrum of **5c**.




Figure S20. $^1\text{H NMR}$ (400 MHz, $\text{CDCl}_3/\text{DMSO-d}_6$) spectrum of **5d**.




Figure S21. $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6) spectrum of **5d**.




Figure S22. ^1H NMR (400 MHz, $\text{CDCl}_3/\text{DMSO-d}_6$) spectrum of **5e**.




Figure S23. ^{13}C NMR (100 MHz, CDCl_3) spectrum of **5e**.

HPLC chromatograms and NMR spectra of products




Figure S24. ^1H NMR (400 MHz, CDCl_3) spectrum of **8a**.




Figure S25. HPLC chromatogram of **8a**.




Figure S26. HPLC chromatogram of racemic standard of **8a**.




Figure S27. $^1\text{H NMR}$ (400 MHz, CDCl_3) spectrum of **8b**.




Figure S28. HPLC chromatogram of **8b**.




Figure S29. HPLC chromatogram of racemic standard of **8b**.




Figure S30. ^1H NMR (400 MHz, CDCl_3) spectrum of **8c**.




Figure S31. HPLC chromatogram of **8c**.




Figure S32. HPLC chromatogram of racemic standard of **8c**.




Figure S33. ¹H NMR (400 MHz, CDCl₃) spectrum of **8d**.




Figure S34. HPLC chromatogram of **8d**.

Peak	Area	t (min)
1	100515,4	24,025
2	109569,8	29,83333




Figure S35. HPLC chromatogram of racemic standard of **8d**.




Figure S36. ^1H NMR (400 MHz, CDCl_3) spectrum of **8e**.




Figure S37. HPLC chromatogram of **8e**.




Figure S38. HPLC chromatogram of racemic standard of **8e**.




Figure S39. ¹H NMR (400 MHz, CDCl₃) spectrum of **8f**.




Figure S40. HPLC chromatogram of **8f**.




Figure S41. HPLC chromatogram of racemic standard of **8f**.




Figure S42. ¹H NMR (400 MHz, CDCl₃) spectrum of **8g**.




Figure S43. HPLC chromatogram of **8g**.




Figure S44. HPLC chromatogram of racemic standard of **8g**.




Figure S45. ^1H NMR (400 MHz, CDCl_3) spectrum of **8h**.




Figure S46. HPLC chromatogram of **8h**.




Figure S47. HPLC chromatogram of racemic standard of **8h**.




Figure S48. ^1H NMR (400 MHz, CDCl_3) spectrum of **8i**.




Figure S49. HPLC chromatogram of **8i**.




Figure S50. HPLC chromatogram of racemic standard of **8i**.




Figure S51. ¹H NMR (400 MHz, CDCl₃) spectrum of **8j**.




Figure S52. HPLC chromatogram of **8j**.




Figure S53. HPLC chromatogram of racemic standard of **8j**.




Figure S54. ^1H NMR (400 MHz, CDCl_3) spectrum of **10**.




Figure S55. HPLC chromatogram of **10**.




Figure S56. HPLC chromatogram of racemic standard of **10**.